{"Clinical Trial ID": "NCT00171340", "Intervention": ["INTERVENTION 1:", "zoledronic acid 4 mg Upstream", "All participants took Letrozole 2.5 mg/day tablets for 5 years from day 1.", "INTERVENTION 2:", "zoledronic acid 4 mg Delayed", "AMD T-score <= -2.0 SD at the lumbar spine or total hip, any clinical fracture unrelated to an asymptomatic trauma or fracture discovered at the visit to the month 36. All participants took Letrozole 2.5 mg/day tablets for 5 years from day 1."], "Eligibility": ["Incorporation criteria:", "Stage I-IIIa Breast cancer", "Recent postmenopausal or postmenopausal", "Recent breast cancer surgery", "Estrogen Positive receptor and/or progesterone receptor positive hormone receptor status", "No prior treatment with letrozole", "Other inclusion criteria defined by the protocol may apply.", "- Exclusion criteria:", "Metastatic diseases", "A bilateral invasive disease", "Clinical or radiological evidence of an existing fracture in the spine or hip", "Previous treatment with bisphosphonates IV in the last 12 months", "Current treatment with oral bisphosphonates (must be discontinued within 3 weeks of initial assessment)", "Use of Tibolone within 6 months", "Previous use of parathyroid hormone for more than one week", "Previous or concomitant malignancy", "Abnormal renal function", "\u2022 History of disease affecting bone metabolism", "Other exclusion criteria defined by the Protocol may apply."], "Results": ["Performance measures:", "Percentage change in bone mineral density (BMD) of the lumbar spine (L2-L4) at 12 months of therapy.", "- Bone mineral density (g/cm^2) of the lumbar spine (L2-L4) measured by X-ray energy absorptiometry (DXA).", "Target date: Baseline, 12 months", "Results 1:", "Title of the arm/group: Zoledronic acid 4 mg at the front", "Description of the arm/group: Zolendronic acid 4 mg Intravenous infusion (IV) 15 minutes every 6 months for 5 years from day 1. All participants took Letrozole 2.5 mg/day tablets for 5 years from day 1.", "Total number of participants analysed: 423", "Average (standard deviation)", "Unit of measure: Percentage change in BMD 2,208 (3,4194)", "Results 2:", "Title of arm/group: Zoledronic acid 4 mg delayed", "Description of the arm/group: Zolendronic acid 4 mg Intravenous infusion (IV) 15 minutes every 6 months from one of the following cases: AMD T-score <= -2.0 SD to the lumbar spine or total hip, any clinical fracture unrelated to an asymptomatic trauma or fracture discovered at the visit to month 36.", "Total number of participants analysed: 418", "Average (standard deviation)", "Unit of measure: Percentage change in BMD -3.617 (4.2151)"], "Adverse Events": ["Undesirable Events 1:", "Total: 133/525 (25.33%)", "Anemia 1/525 (0.19%)", "1/525 (0.19%)", "Acute myocardial infarction 2/525 (0.38%)", "Angina pectoris 3/525 (0.57%)", "Unstable Angina 1/525 (0.19%)", "Incompetence of aortic valve 1/525 (0.19%)", "Arrhythmia 0/525 (0.00 %)", "Atrial fibrillation 1/525 (0.19%)", "- Complete auriventricular block 0/525 (0.00 %)", "Cardiac arrest 0/525 (0.00 %)", "Adverse Events 2:", "Total: 124/535 (23.18 per cent)", "Anemia 1/535 (0.19%)", "- Febrile neutropenia 0/535 (0.00 %)", "- Acute myocardial infarction 0/535 (0.00 %)", "Angina pectoris 2/535 (0.37%)", "Unstable Angina 0/535 (0.00 %)", "Incompetence of aortic valve 1/535 (0.19%)", "Arrhythmia 1/535 (0.19%)", "Atrial fibrillation 4/535 (0.75%)", "1/535 (0.19%)", "Cardiac arrest 2/535 (0.37%)"]}